Clinical Trial Update: Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating methotrexate, erlotinib, and celecoxib for recurrent/metastatic oral cavity and lip cancers; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lip Cancer
• Oral Cavity Cancer

Drugs mentioned

• CELEBREX (Celecoxib)
• Tarceva (erlotinib)
• Trexall (Methotrexate)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma | Phase 2 | Status: RECRUITING